{"disease":{"id":"rifampicin-resistant-tuberculosis","name":"Rifampicin-resistant Tuberculosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[],"pipeline":[{"drug_id":"rifampin","indication_name":"Rifampicin-resistant Tuberculosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03044158","title":"GeneXpert Performance Evaluation for Linkage to Tuberculosis Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":10644,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT05081401","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04062201","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":402,"lead_sponsor_name":"Wits Health Consortium (Pty) Ltd","has_results":false},{"nct_id":"NCT06565806","title":"French National Cohort of Patients With Rifampicin-Resistant Tuberculosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06081361","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":186,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT07393438","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT07268664","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT05586230","title":"Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07191834","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Wuhan Pulmonary Hospital","has_results":false},{"nct_id":"NCT07170800","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"WestVac Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT06701136","title":"Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Shanghai Jiatan Pharmatech Co., Ltd","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}